Although direct evidence remains limited, novel antidiabetic therapies such as SGLT2 inhibitors and GLP-1 receptor agonists through improved metabolic control and modulation of host immune function could influence susceptibility to opportunistic ocular infections, including fungal keratitis. The gene discussed is SLC5A2; the disease is fungal keratitis.